Evidence map›Paper›PMID 39962959›Full record

ReviewCurrent organic synthesis2025

Stimuli-responsive Graphene-polysaccharide Nanocomposites for Drug Delivery and Tissue Engineering.

Arman Seifallahi Teymourlouei, Seyed Morteza Naghib, M R Mozafari

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current organic synthesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arman Seifallahi TeymourloueiNanotechnology Department, School of Advanced Technologies, Iran University of Science and Technology (IUST), Tehran, 1684613114, Iran.
Seyed Morteza NaghibNanotechnology Department, School of Advanced Technologies, Iran University of Science and Technology (IUST), Tehran, 1684613114, Iran.
M R MozafariAustralasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton, VIC, 3168, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural polysaccharide-based nanoparticles are known for their non-toxic nature and diverse medical applications. Graphene oxide (GO) nanoparticles show potential in cancer treatment due to their ability to target medication delivery and influence ROS generation. These nanocomposites are versatile in gene transport, therapy, and photodynamic therapy, especially when surface-modified. Proper dispersion and functionalization of GO in polymer matrices are crucial, with examples like hyaluronic acid-functionalized GO offering versatile platforms for cancer drug administration. The potential of graphene oxide extends to cancer phototherapy, electronic nanowires, hydrogels, antibacterial nanocomposites, and environmental applications. When activated by polysaccharides, graphene-based nanocomposites exhibit anti-inflammatory and anticancer properties, making them valuable across various industries, including water treatment.

Indexed as

Drug Delivery SystemsGraphiteNanocompositesPolysaccharidesTissue EngineeringAntineoplastic AgentsHumansAntineoplastic Agentsgraphene oxideGraphitePolysaccharidesgraphenenanocomposite drug deliverynanomaterials.polysaccharidesStimuli-responsivetissue engineering

Identifiers

PMID39962959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.